Skip to content
Screener

Erasca, Inc. ERAS Price / book

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Eli Lilly logo
Eli LillyLLY
31.6×-6.7×
Pfizer logo
PfizerPFE
1.8×+0.2×
Amgen logo
AmgenAMGN
16.7×-3.4×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
15.3×+11.3×
Tango Therapeutics logo
Tango TherapeuticsTNGX
7.6×+6.7×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788

FAQ

What is Erasca, Inc.'s price / book?
Erasca, Inc. (ERAS) reported price / book of 12.8× in Q1 2026.
How has Erasca, Inc.'s price / book changed year-over-year?
Erasca, Inc.'s price / book increased by 1215.5% year-over-year, from 1× to 12.8×.
What is the long-term trend for Erasca, Inc.'s price / book?
Over 4 years (2021 to 2025), Erasca, Inc.'s price / book has grown at a -15.7% compound annual growth rate (CAGR), from 6.4× to 3.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Erasca, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude